Influence of obesity on pharmacokinetics and analgesic effect of ketoprofen administered intravenously to patients after laparoscopic cholecystectomy.
Ketoprofen
Obesity
Pain assessment
Pharmacokinetics
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
12
07
2019
accepted:
11
10
2019
revised:
19
09
2019
pubmed:
13
2
2020
medline:
13
4
2021
entrez:
13
2
2020
Statut:
ppublish
Résumé
Ketoprofen is an analgesic drug commonly applied in the postoperative period, e.g., to patients after laparoscopic cholecystectomy. Many patients who undergo this procedure are obese. As pathophysiological changes are observed in obesity, the efficacy of ketoprofen may be altered in this group of patients. The aim of the study was to compare the pharmacokinetic parameters and analgesic effect of ketoprofen administered to obese and non-obese patients after laparoscopic cholecystectomy. The study was conducted on 41 patients after laparoscopic cholecystectomy, who were divided into two groups: obese (n = 21) and non-obese (n = 20). Ketoprofen was administered intravenously at a dose of 100 mg. Plasma ketoprofen concentrations were measured by means of validated high-performance liquid chromatography with ultraviolet detection. The pharmacokinetic parameters of the drug were calculated using the non-compartmental method. Additionally, pain intensity was assessed during the study using NRS scale. The obese patients had significantly lower AUC The drug was eliminated faster and the analgesic effect of ketoprofen in the obese patients was decreased as compared with the non-obese subjects. However, pain intensity did not increase to the level, which required additional analgesic treatment. Therefore, it seems that dosage adjustment of intravenous ketoprofen is not necessary in obese patients.
Sections du résumé
BACKGROUND
BACKGROUND
Ketoprofen is an analgesic drug commonly applied in the postoperative period, e.g., to patients after laparoscopic cholecystectomy. Many patients who undergo this procedure are obese. As pathophysiological changes are observed in obesity, the efficacy of ketoprofen may be altered in this group of patients. The aim of the study was to compare the pharmacokinetic parameters and analgesic effect of ketoprofen administered to obese and non-obese patients after laparoscopic cholecystectomy.
METHODS
METHODS
The study was conducted on 41 patients after laparoscopic cholecystectomy, who were divided into two groups: obese (n = 21) and non-obese (n = 20). Ketoprofen was administered intravenously at a dose of 100 mg. Plasma ketoprofen concentrations were measured by means of validated high-performance liquid chromatography with ultraviolet detection. The pharmacokinetic parameters of the drug were calculated using the non-compartmental method. Additionally, pain intensity was assessed during the study using NRS scale.
RESULTS
RESULTS
The obese patients had significantly lower AUC
CONCLUSIONS
CONCLUSIONS
The drug was eliminated faster and the analgesic effect of ketoprofen in the obese patients was decreased as compared with the non-obese subjects. However, pain intensity did not increase to the level, which required additional analgesic treatment. Therefore, it seems that dosage adjustment of intravenous ketoprofen is not necessary in obese patients.
Identifiants
pubmed: 32048255
doi: 10.1007/s43440-019-00042-9
pii: 10.1007/s43440-019-00042-9
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents, Non-Steroidal
0
Ketoprofen
90Y4QC304K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
763-768Références
World Health Organization. Global report on obesity. 2016. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua = 1 . Accessed 8 Feb 2018.
Hanley MJ, Abernethy Darrell R, Greenblatt David J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.
doi: 10.2165/11318100-000000000-00000
Edelmana AB, Cheralaab G, Bluec SW, Eriksonc DW, Jensena JT. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception. 2016;94(1):52–7.
doi: 10.1016/j.contraception.2016.03.006
Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47(4):259–68.
doi: 10.1016/j.ijantimicag.2016.01.009
Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347–52.
doi: 10.1097/00042737-200012120-00015
Goyal V, Nagpal N, Gupta M, Kapoor R. Prospective study to predict the preoperative risk factors for conversion of laparoscopic to open cholecystectomy. J Contemp Med Surg Radiol. 2017;2(4):148–52.
Boccara G, Chaumeron A, Pouzeratte Y, Mann C. The preoperative administration of ketoprofen improves analgesia after laparoscopic cholecystectomy in comparison with propacetamol or postoperative ketoprofen. Br J Anaesth. 2005;94(3):347–51.
doi: 10.1093/bja/aei056
Summary of product characteristics Ketonal
Krawczyk M, Wordliczek J, Czupryna A, Dobrogowski J, Dobosz M, Gaszyński W, Andziak P, Misiołek H, Dziki A. The recommendations for perioperative pain relief in general surgery. Pol Przegl Chir. 2012;84(9):476–84.
pubmed: 23241575
Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304.
doi: 10.2165/11599410-000000000-00000
Jaramillo-Morales OA, Espinosa-Juárez JV, García-Martínez BA, López-Muñoz FJ. Ketoprofen and antinociception in hypo-oestrogenic Wistar rats fed on a high sucrose diet. Eur J Pharmacol. 2016;5(788):168–75.
doi: 10.1016/j.ejphar.2016.06.030
Roda A, Sabatini L, Mirasoli M, Baraldini M, Roda E. Bioavailability of a new ketoprofen formulation for once-daily oral administration. Int J Pharm. 2002;241(1):165–72.
doi: 10.1016/S0378-5173(02)00230-2
Guideline on bioanalytical method validation. European Medicines Agency (EMEA/CHMP/EWP/192217/2009 Rev.1 Corr. 2**). London, 21 July 2011.
van Rongen A, Välitalo PAJ, Peeters MYM, Boerma D, Huisman FW, van Ramshorst B, van Dongen EPA, van den Anker JN, Knibbe CAJ. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin Pharmacokinet. 2016;55(7):833–47.
doi: 10.1007/s40262-015-0357-0
Porażka J, Szałek E, Połom W, Czajkowski M, Grabowski T, Matuszewski M, Grześkowiak E. Influence of obesity and type 2 diabetes mellitus on the pharmacokinetics of tramadol after single oral dose administration. Eur J Drug Metab Pharmacokinet. 2019;44(4):579–84.
doi: 10.1007/s13318-019-00543-1
Toutain P-L, Bousquet Melou A. Free drug fraction versus free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2003;25(6):460–3.
doi: 10.1046/j.1365-2885.2002.00442.x
Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE, Sahajwalla CG. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):7–89.
doi: 10.1038/clpt.2011.104
Knibbe CAJ, Brill MJE, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55(1):149–67.
doi: 10.1146/annurev-pharmtox-010814-124354
Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. Br J Anaesth. 2011;107(4):619–26.
doi: 10.1093/bja/aer195
Pieretti S, Di Giannuario A, Di Giovannandrea R, Marzoli F, Piccaro G, Minosi P, Aloisi AM. Gender differences in pain and its relief. Ann Ist Super Sanita. 2016;52(2):184–9.
pubmed: 27364392